NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 193 filers reported holding NEKTAR THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,834,883 | -29.4% | 1,696,851 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $5,429,923 | -15.8% | 1,696,851 | 0.0% | 0.00% | -50.0% |
| Q2 2022 | $6,448,034 | -25.0% | 1,696,851 | +6.3% | 0.00% | 0.0% |
| Q1 2022 | $8,600,413 | -64.0% | 1,595,624 | -9.7% | 0.00% | -60.0% |
| Q4 2021 | $23,878,000 | -7.1% | 1,767,420 | +23.4% | 0.01% | -16.7% |
| Q3 2021 | $25,715,000 | -17.3% | 1,431,820 | -21.0% | 0.01% | -14.3% |
| Q2 2021 | $31,102,000 | -16.2% | 1,812,494 | -2.3% | 0.01% | -12.5% |
| Q1 2021 | $37,094,000 | -0.4% | 1,854,692 | -15.4% | 0.01% | -11.1% |
| Q4 2020 | $37,250,000 | +2.5% | 2,191,199 | 0.0% | 0.01% | -10.0% |
| Q3 2020 | $36,352,000 | -33.1% | 2,191,199 | -6.6% | 0.01% | -37.5% |
| Q2 2020 | $54,333,000 | +25.2% | 2,345,993 | -3.5% | 0.02% | +6.7% |
| Q1 2020 | $43,411,000 | -17.3% | 2,432,006 | 0.0% | 0.02% | 0.0% |
| Q4 2019 | $52,495,000 | +16.1% | 2,432,006 | -2.0% | 0.02% | +7.1% |
| Q3 2019 | $45,219,000 | -44.3% | 2,482,501 | +8.9% | 0.01% | -44.0% |
| Q2 2019 | $81,135,000 | +24.6% | 2,280,364 | +17.6% | 0.02% | +19.0% |
| Q1 2019 | $65,138,000 | +2.2% | 1,938,621 | 0.0% | 0.02% | -12.5% |
| Q4 2018 | $63,723,000 | -38.8% | 1,938,621 | +13.5% | 0.02% | -29.4% |
| Q3 2018 | $104,124,000 | +29.8% | 1,708,067 | +3.9% | 0.03% | +21.4% |
| Q2 2018 | $80,239,000 | -46.3% | 1,643,219 | +16.9% | 0.03% | -48.1% |
| Q1 2018 | $149,381,000 | +3.2% | 1,405,805 | -42.0% | 0.05% | +3.8% |
| Q4 2017 | $144,808,000 | +122.3% | 2,424,789 | -10.6% | 0.05% | +108.0% |
| Q3 2017 | $65,129,000 | +22.8% | 2,713,717 | 0.0% | 0.02% | +19.0% |
| Q2 2017 | $53,053,000 | -3.9% | 2,713,717 | +15.4% | 0.02% | -8.7% |
| Q1 2017 | $55,209,000 | +74.9% | 2,352,325 | -8.6% | 0.02% | +64.3% |
| Q4 2016 | $31,574,000 | -16.4% | 2,573,278 | +11.8% | 0.01% | -22.2% |
| Q3 2016 | $37,768,000 | +15.3% | 2,301,709 | 0.0% | 0.02% | +12.5% |
| Q2 2016 | $32,753,000 | +3.5% | 2,301,709 | 0.0% | 0.02% | 0.0% |
| Q1 2016 | $31,648,000 | -12.0% | 2,301,709 | +7.8% | 0.02% | -11.1% |
| Q4 2015 | $35,961,000 | +53.7% | 2,134,205 | 0.0% | 0.02% | +50.0% |
| Q3 2015 | $23,391,000 | -12.4% | 2,134,205 | 0.0% | 0.01% | -7.7% |
| Q2 2015 | $26,699,000 | +13.7% | 2,134,205 | 0.0% | 0.01% | +8.3% |
| Q1 2015 | $23,476,000 | -10.9% | 2,134,205 | +25.5% | 0.01% | -7.7% |
| Q4 2014 | $26,353,000 | +84.3% | 1,700,173 | +43.5% | 0.01% | +62.5% |
| Q3 2014 | $14,298,000 | -40.6% | 1,184,581 | -36.9% | 0.01% | +33.3% |
| Q2 2014 | $24,052,000 | +111.5% | 1,876,190 | +100.0% | 0.01% | 0.0% |
| Q1 2014 | $11,370,000 | +6.8% | 938,095 | 0.0% | 0.01% | 0.0% |
| Q4 2013 | $10,647,000 | +7.6% | 938,095 | -0.9% | 0.01% | 0.0% |
| Q3 2013 | $9,893,000 | +11.3% | 946,695 | +23.0% | 0.01% | 0.0% |
| Q2 2013 | $8,889,000 | +45.8% | 769,670 | +38.9% | 0.01% | +50.0% |
| Q1 2013 | $6,097,000 | +3.0% | 554,268 | 0.0% | 0.00% | 0.0% |
| Q3 2012 | $5,920,000 | +25.4% | 554,268 | 0.0% | 0.00% | 0.0% |
| Q2 2012 | $4,722,000 | – | 554,268 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |